Skip to main content
Premium Trial:

Request an Annual Quote

Japan's Yamatake Licenses OGT's Oligo IP to Develop Microarrays

NEW YORK (GenomeWeb News) – Japan’s Yamatake has licensed Oxford Gene Technology’s oligonucleotide microarray patents to make and sell its own arrays, OGT said today.
 
Yamatake will manufacture gemkey microarrays using in situ synthesis. Yamatake is the only Japanese company using in situ synthesis, said Michael Bennett, OGT’s vice president of licensing.
 
The company will market the microarrays through its distributor, Sigma-Aldrich Japan.
 
The license will remain valid for the patents’ lifetime.
 
Yamatake is the second Japanese company this month to license the patents from OGT: Japan’s NGK Insulators signed a similar deal Aug. 1.
 
Financial details were not disclosed.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.